Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20486285 | 0.82 | MEN1 (0.35) | ESR1 | |
| SCHEMBL456770 | 0.82 | — | — | |
| SCHEMBL20377294 | 0.80 | ESR2 (0.36) | TSHRESR1 | |
| SCHEMBL28185249 | 0.80 | — | — | |
| Phosphoric Acid SCHEMBL305359 | 0.74 | ALDH1A1 (0.36) | TSHRALDH1A1 | |
| Ether SCHEMBL5066675 | 0.71 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL20377292 | 0.70 | PTPN7 (0.31) | ALDH1A1 | |
| SCHEMBL28784921 | 0.68 | VCP (0.30) | — | |
| Bicarbonate SCHEMBL10006506 | 0.67 | CA1 (0.36) | ESR1 | |
| Citric Acid SCHEMBL3862968 | 0.67 | ALDH1A1 (0.56) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-10-29 | — | — | US | disclosed |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2018-09-06 | — | — | US | disclosed |
| EP-3348548-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456405-B2 | Nitric oxide-releasing prodrug molecule of substituted quinazolines | PTGIS, NOS1, NOS2 | TSHR 3654/4885SMN1; SMN2 3576/4885ESR1 3879/4885 |
| US-20180250305-A1 | NITRIC OXIDE-RELEASING PRODRUG MOLECULE | NOS1, NOS2, PTGIS | TSHR 3093/4885SMN1; SMN2 3878/4885ESR1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.